-
Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy". With the official inauguration of Argentina's new president Javier Mile la ... -
AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
On December 26th, AstraZeneca announced that it had signed a final agreement on its acquisition proposal for Genxi Biotechnology. This proposed acquisition will add GC012F CAR-T cell therapy to Astra ... -
Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
Johnson&Johnson announced on the 23rd that the US FDA has approved its Opsynvi monotherapy combination therapy for long-term treatment of adult patients with pulmonary arterial hypertension (PAH) cla ... -
12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
The oral therapy of Novo Nordisk with a weight loss of over 13% in 12 weeks has been applied for clinical trials in China. According to the official website of the Drug Evaluation Center (CDE) of the ... -
Baishime Squibb CAR-T therapy approved by the US FDA
On May 30th local time, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved an extended indication for its CAR-T therapy, Breyanzi (lisocabtagene maraleucel; li ... -
GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
On July 3rd, GlaxoSmithKline (GSK) and CureVac N.V. announced that they had restructured their existing partnership into a new licensing agreement, allowing both companies to prioritize investment an ...